Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers

被引：0
作者：
Guillaume Beinse
Pierre-Alexandre Just
Marie-Aude Le Frere Belda
Pierre Laurent-Puig
Sebastien Jacques
Meriem Koual
Simon Garinet
Karen Leroy
Nicolas Delanoy
Helene Blons
Claire Gervais
Catherine Durdux
Charles Chapron
François Goldwasser
Benoit Terris
Cecile Badoual
Valerie Taly
Anne-Sophie Bats
Bruno Borghese
Jérôme Alexandre
机构：
[1] Sorbonne Université,Centre de Recherche des Cordeliers, « Equipe labélisée Ligue Contre le Cancer », CNRS SNC 5096
[2] Université de Paris Cité,Institut du Cancer Paris CARPEM, AP
[3] INSERM,HP, APHP.Centre, Department of Medical Oncology
[4] Hopital Cochin,Institut du Cancer Paris CARPEM, AP
[5] Hopital Cochin,HP, APHP.Centre, Department of Pathology
[6] Université de Paris Cité,Institut du Cancer Paris CARPEM, AP
[7] Hopital Européen Georges Pompidou,HP, APHP.Centre, Department of Pathology
[8] Hopital Européen Georges Pompidou,Institut du Cancer Paris CARPEM, AP
[9] Institut du Cancer Paris CARPEM,HP, APHP.Centre, Department of Biology
[10] AP-HP,Institut du Cancer Paris CARPEM, AP
[11] APHP.Centre,HP, APHP.Centre, Department of Gynecological Surgery
[12] GENOM’IC platform,Institut du Cancer Paris CARPEM, AP
[13] Institut Cochin,HP, APHP.Centre, Department of Medical Oncology
[14] Hopital Européen Georges Pompidou,Institut du Cancer Paris CARPEM, AP
[15] Hopital Européen Georges Pompidou,HP, APHP.Centre, Department of Radiotherapy
[16] Hopital Européen Georges Pompidou,Institut du Cancer Paris CARPEM, AP
[17] Hopital Cochin,HP, APHP.Centre, Department of Gynecological Surgery
来源：
British Journal of Cancer | 2022年 / 127卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1123 / 1132
页数：9
相关论文
共 45 条
  • [41] RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects
    Mandelker, Diana SReis-FilhoReis-Filho
    Mukherjee, Semanti
    Setton, Jeremy
    Selenica, Pier
    Kemel, Yelena
    Ceyhan-Birsoy, Ozge
    Sheehan, Margaret
    Tkachuk, Kaitlyn
    Brown, David N.
    Powell, Simon
    Weigelt, Britta
    Robson, Mark E.
    Riaz, Nadeem
    Offit, Kenneth
    Reis-Filho, Jorge S.
    CANCER RESEARCH, 2020, 80 (04)
  • [42] IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors
    Abed, Monah
    Munoz, Diana
    Seshadri, Vidya
    Federowicz, Steve
    Rao, Arjun A.
    Bhupathi, Deepthi
    Liimatta, Marya
    Ousterhout, Rita
    Jaipuri, Firoz
    Neilan, Claire
    Lackner, Mark
    White, Mike
    Mounir, Zineb
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers
    Vankayalapati, Hariprasad
    Yerramreddy, Venkatakrishnareddy
    Zhou, Jinhua
    Handler, Jeffrey A.
    Appalaneni, Rajendra P.
    Kancherla, Ramamohan R.
    Wu, Roy J.
    Takemori, Hiroshi
    Whitehurst, Angelique
    Jazaeri, Amir Anthony
    Coleman, Robert L.
    Lu, Zhen
    Bast, Robert C.
    CANCER RESEARCH, 2017, 77
  • [44] Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial
    Belotte, Jimmy
    Felicetti, Brunella
    Baines, Amanda J.
    YoussefAgha, Ahmed
    Rojas-Espaillat, Luis
    Ortiz, Ana Godoy
    Provencher, Diane
    Vazquez, Raul Marquez
    Cortijo, Lucia Gonzalez
    Zeng, Xing
    TRIALS, 2024, 25 (01)
  • [45] Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis
    Pimentel, I.
    Lema Roso, L.
    Ramos Vazquez, M.
    Garcia Saenz, J. A.
    Palacios-Ozores, P.
    De la Haba Rodriguez, J.
    Blanch, S.
    Prat, A.
    Ales Martinez, J. E.
    Alba Conejo, E.
    Balmana, J.
    Perez Garcia, J. M.
    Sampayo-Cordero, M.
    Malfettone, A.
    Cortes, J.
    Llombart Cussac, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S657 - S657
12345